NCT06381973

Brief Summary

ELTGOL (Slow Expiration with the Opened Glottis in the Lateral posture) is an airway clearance technique performed in the lateral decubitus position. This technique focuses on optimizing ventilation of the infralateral lung (when the subject is lying in the lateral posture) to enhance local air-liquid interaction. Previous studies on ventilation differences between the infra- and supralateral lungs were conducted on healthy, young, male subjects, without the application of thoracic or abdominal pressure. This study aimed to assess ventilation distribution in right lateral recumbency in patients with chronic obstructive pulmonary disease (COPD), as well as healthy individuals, and investigate the impact of thoracic and abdominal manual pressures during ELTGOL on ventilation distribution.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
33

participants targeted

Target at P25-P50 for not_applicable chronic-obstructive-pulmonary-disease

Timeline
Completed

Started Apr 2024

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 15, 2024

Completed
Same day until next milestone

Study Start

First participant enrolled

April 15, 2024

Completed
9 days until next milestone

First Posted

Study publicly available on registry

April 24, 2024

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 16, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 16, 2025

Completed
Last Updated

April 23, 2026

Status Verified

April 1, 2026

Enrollment Period

1.1 years

First QC Date

April 15, 2024

Last Update Submit

April 22, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Impedance variation using Electrical Impedance Tomography

    Impedance change in the right and left lungs

    2 minutes during intervention

Study Arms (5)

ELTGOL_Physio

ACTIVE COMPARATOR

ELTGOL + Manual pressure of the physiotherapist

Behavioral: ELTGOL_Physio

ELTGOL_Auto

ACTIVE COMPARATOR

ELTGOL performed autonomously

Behavioral: ELTGOL_Auto

PEP

ACTIVE COMPARATOR

Positive expiratory pressure (PEP)

Device: PEP

1L-Tidal-Breathing

ACTIVE COMPARATOR

Tidal-breathing of 1 liter per breath

Behavioral: 1L-Tidal-Breathing

Spontaneous Breathing

ACTIVE COMPARATOR
Behavioral: Spontaneous Breathing

Interventions

ELTGOL_PhysioBEHAVIORAL

The subject will be asked to slowly exhale with the glottis opened in the right lateral posture. The physiotherapist will accompany the subject by gently applying manual pressure on the chest wall and the abdomen during expiratory phases.

ELTGOL_Physio
ELTGOL_AutoBEHAVIORAL

The subject will be asked to slowly exhale with the glottis opened in the right lateral posture. The physiotherapist will not intervene in this arm.

ELTGOL_Auto
PEPDEVICE

The subject will be asked to exhale through a positive expiratory pressure (PEP) device (Threshold PEP) while being in the right lateral posture.

PEP

The subject will be asked to breath with a fixed tidal-breathing of 1 liter per breath (monitored via a spirometer) while being in the right lateral posture.

1L-Tidal-Breathing

The subject will be asked to breath spontaneously while being in the right lateral posture.

Spontaneous Breathing

Eligibility Criteria

Age40 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Healthy subjects: No acute or chronic respiratory disease, normal lung function, non-smoker.
  • Patients with COPD: forced expiratory volume at one second (FEV1) ≤ 80% predicted value, in stable state.

You may not qualify if:

  • Healthy subjects: obesity (BMI \> 35kg/m²); active or former smoker; severe scoliosis; cardiovascular or neuromuscular disease; active implant (cardiac pacemaker or an implantable cardioverter-defibrillator (ICD); thoracic skin lesion.
  • Patients with COPD: obesity (BMI \> 35kg/m²); severe scoliosis; severe cardiovascular disease; neuromuscular disease; active implant (cardiac pacemaker or an implantable cardioverter-defibrillator (ICD); thoracic skin lesion.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cliniques universitaires Saint-Luc

Brussels, Brussels Capital, 1200, Belgium

Location

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Condition Hierarchy (Ancestors)

Lung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

April 15, 2024

First Posted

April 24, 2024

Study Start

April 15, 2024

Primary Completion

May 16, 2025

Study Completion

May 16, 2025

Last Updated

April 23, 2026

Record last verified: 2026-04

Locations